CompanyVTRSNasdaqCanonsburg, PA

Viatris Inc.

Viatris is a global healthcare company supplying medicines across multiple therapeutic areas to approximately 1 billion patients annually.

SEC EDGAR ClinicalTrials.gov investor.viatris.com

424B3Sep 25Latest SEC filing

Sep 15Latest story

September 2026

FDA approves labeling supplement for Mylan's Amnesteem (isotretinoin)

Sep 15Regulatory decisionisotretinoin Viatris Inc.

Viatris registers Phase 4 abuse-potential trial of gabapentin plus oxycodone

Sep 10Trial updategabapentin oxycodone

August 2026

Viatris: Ocuphire trial results posted, Amnesteem label update, gabapentin abuse study completed

Aug 21Weekly roundup, 3 itemsalprazolam gabapentin

Mylan wins FDA approval for labeling supplement on metformin ER tablets

Aug 11Regulatory decisionmetformin Viatris Inc.

Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 update

Aug 6Quarterly updatevarenicline Viatris Inc.

Mylan gets ANDA labeling supplement approved for fenofibrate tablets

Aug 5Regulatory decisionfenofibrate Viatris Inc.

July 2026

Viatris-collaborated trial registered comparing Yupelri/Perforomist combo to standard COPD therapy

Jul 23Trial updateformoterol revefenacin

Mylan doxepin label update approved; Viatris-linked contact lens comfort trial begins recruiting

Jul 16Weekly roundup, 2 itemsdoxepin Viatris Inc.

Viatris amends and restates yen term loan facility with Mizuho as agent

Jul 1PartnershipViatris Inc.